The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A multicenter phase II trial of the LH-RH analogue and an aromatase inhibitor combination in premenopausal patients with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: JMTO BC08-01.
Reiki Nishimura
No relevant relationships to disclose
Keisei Anan
No relevant relationships to disclose
Yutaka Yamamoto
No relevant relationships to disclose
Kenji Higaki
No relevant relationships to disclose
Maki Tanaka
No relevant relationships to disclose
Kenji Shibuta
No relevant relationships to disclose
Yasuaki Sagara
No relevant relationships to disclose
Shinji Ohno
No relevant relationships to disclose
Shigeru Tsuyuki
No relevant relationships to disclose
Takahiro Mase
No relevant relationships to disclose
Satoshi Teramukai
No relevant relationships to disclose